[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sophia Genetics Sa (SOPH)

Sophia Genetics Sa (SOPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 347,909
  • Shares Outstanding, K 68,486
  • Annual Sales, $ 77,270 K
  • Annual Income, $ -79,000 K
  • EBIT $ -72 M
  • EBITDA $ -63 M
  • 60-Month Beta 1.01
  • Price/Sales 4.44
  • Price/Cash Flow N/A
  • Price/Book 7.51

Options Overview Details

View History
  • Implied Volatility 74.03% (-6.76%)
  • Historical Volatility 53.65%
  • IV Percentile 2%
  • IV Rank 4.42%
  • IV High 442.01% on 10/22/25
  • IV Low 57.03% on 09/04/25
  • Expected Move (DTE 21) 0.53 (10.23%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 801
  • Volume Avg (30-Day) 184
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 4,175
  • Open Int (30-Day) 2,823
  • Expected Range 4.62 to 5.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) +356,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.44 +10.76%
on 05/18/26
5.67 -13.23%
on 05/08/26
-0.08 (-1.60%)
since 04/28/26
3-Month
4.01 +22.85%
on 03/04/26
5.67 -13.23%
on 05/08/26
+0.42 (+9.33%)
since 02/27/26
52-Week
2.59 +89.96%
on 06/20/25
5.70 -13.68%
on 01/22/26
+2.05 (+71.43%)
since 05/28/25

Most Recent Stories

More News
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

LONDON , May 13, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers,...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS Reports First Quarter 2026 Results

BOSTON and ROLLE, Switzerland , May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS: Whether Platform Economics or Customer Concentration Wins the Narrative

Barchart Research What to Expect from SOPH Earnings SOPH Generated May 4, 2026 Current Price $5.30 Consensus Rating Strong Buy Average Move 5.33% SOPHiA GENETICS: Whether Platform Economics or Customer...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

BOSTON and ROLLE, Switzerland , April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results...

SOPH : 5.00 (-1.57%)
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

SAN DIEGO and NEW YORK , April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

BOSTON and ROLLE, Switzerland , March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference

BOSTON and ROLLE, Switzerland , Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026

BOSTON and ROLLE, Switzerland , Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

BOSTON and ROLLE, Switzerland , Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest...

SOPH : 5.00 (-1.57%)
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO

SOPH : 5.00 (-1.57%)

Business Summary

SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights...

See More

Key Turning Points

3rd Resistance Point 5.31
2nd Resistance Point 5.21
1st Resistance Point 5.14
Last Price 5.00
1st Support Level 4.97
2nd Support Level 4.87
3rd Support Level 4.80

See More

52-Week High 5.70
Last Price 5.00
Fibonacci 61.8% 4.51
Fibonacci 50% 4.14
Fibonacci 38.2% 3.78
52-Week Low 2.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.